Literature DB >> 22780867

Application of decoy oligonucleotides as novel therapeutic strategy: a contemporary overview.

Mohammad Zaki Ahmad1, Sohail Akhter, Neha Mallik, Mohammad Anwar, Wajda Tabassum, Farhan Jalees Ahmad.   

Abstract

Molecular therapy is emerging as a potential strategy for the treatment of many diseases. Correct regulation of gene expression is essential for both, to normal development and proper functioning of the all the organisms. Even after four decades of intensive research, it is still a major problem from regulatory and technical point of view, to replace defective genes. The technology of decoy oligonucleotides has received considerable attention to treat and cure a variety of diseases and abnormal physiological conditions, because they provide a rational way to design and selective regulation of a specific gene expression. Decoy oligonucleotides are widely used as inhibitors of specific gene expression because they can offer exciting possibility of expression and blocking of a particular gene without any changes in the functions of other genes. Advances in the decoy oligonucleotides are rapidly paving the way to new insights into the origin and treatment of inflammatory, cancer and/or other immune disorders. The review covers the progress achieved towards the development of decoy oligonucleotides as a potential strategy in a new class of molecular therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22780867     DOI: 10.2174/157016313804998898

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  6 in total

1.  Production of DNA minicircles less than 250 base pairs through a novel concentrated DNA circularization assay enabling minicircle design with NF-κB inhibition activity.

Authors:  Thomas Thibault; Jeril Degrouard; Patrick Baril; Chantal Pichon; Patrick Midoux; Jean-Marc Malinge
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

Review 2.  Skeletal muscle atrophy: disease-induced mechanisms may mask disuse atrophy.

Authors:  C J Malavaki; G K Sakkas; G I Mitrou; A Kalyva; I Stefanidis; K H Myburgh; C Karatzaferi
Journal:  J Muscle Res Cell Motil       Date:  2016-01-04       Impact factor: 2.698

Review 3.  Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides.

Authors:  Leila Farahmand; Behrad Darvishi; Keivan Majidzadeh-A
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

4.  SIDT2 mediates gymnosis, the uptake of naked single-stranded oligonucleotides into living cells.

Authors:  Masayuki Takahashi; Viorica Raluca Contu; Chihana Kabuta; Katsunori Hase; Yuuki Fujiwara; Keiji Wada; Tomohiro Kabuta
Journal:  RNA Biol       Date:  2017-04-17       Impact factor: 4.652

Review 5.  Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension.

Authors:  Kazufumi Nakamura; Hiromi Matsubara; Satoshi Akagi; Toshihiro Sarashina; Kentaro Ejiri; Norifumi Kawakita; Masashi Yoshida; Toru Miyoshi; Atsuyuki Watanabe; Nobuhiro Nishii; Hiroshi Ito
Journal:  J Clin Med       Date:  2017-04-29       Impact factor: 4.241

6.  Effects of miR-939 and miR-376A on ulcerative colitis using a decoy strategy to inhibit NF-κB and NFAT expression.

Authors:  Yongwei Lin; Zhipeng Zhou; Lang Xie; Yongsheng Huang; Zhenghua Qiu; Lili Ye; Chunhui Cui
Journal:  Eur J Histochem       Date:  2022-02-15       Impact factor: 3.188

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.